微流控芯片分析M4患者CD14^+单核细胞中MPO表达  

Microfluidic cell chip method to analyze CD14^+ monocyte myeloperoxidase expression in acute myelomonocytic leukemia patients

作　　者：宋敬敬[1] 李晓亮[1] 兰杰[1] 孙朝 葛鹏[3] 洪程程 孙续国[1] 

机构地区：[1]天津医科大学医学检验学院,天津市300203 [2]天津市北洋医学检测仪器与技术研究所 [3]天津医科大学肿瘤医院检验科

出　　处：《中国肿瘤临床》2014年第12期771-775,共5页Chinese Journal of Clinical Oncology

基　　金：国家科技型中小企业创新基金(编号:DL20121120)资助~~

摘　　要：目的:建立基于微流控细胞芯片技术分析CD14+单核细胞髓过氧化物酶(Myeloperoxidase,MPO)的方法,初步探讨急性粒-单核细胞白血病(M4)患者CD14+单核细胞的MPO表达。方法:以聚二甲基硅氧烷(PDMS)为基质材料,二次模塑成型工艺制备微流控细胞芯片。选取临床诊断M4患者48例,骨髓象大致正常患者52例作为对照组。设定微流控芯片检测单核细胞MPO方法,测定细胞MPO阳性率和程度。应用微流控细胞芯片法分析M4患者和对照组CD14+单核细胞的MPO表达。结果:设计微流控单细胞分析芯片,粒细胞能够进入相应微流控通道,可分离血细胞,但是白细胞周围存在影形细胞现象,而细胞形态未见有明显改变。M4患者骨髓细胞CD14+单核细胞MPO阳性率和活性明显高于对照组(P<0.05)。结论:应用微流控单细胞技术分析CD14+单核细胞MPO表达,结果显示M4患者CD14+单核细胞MPO活性明显高于对照组,有可能作为辅助检查标志物。Objective：A method that is based on microfluidic cell chip technology was developed for the first time to analyze CD14＋monocyte myeloperoxidase （MPO） expression in myelomonocytic leukemia （M4） patients. CD14＋monocyte MPO expression in M4 patients was preliminarily discussed. Methods：a. The chip was prepared by using polydimethylsiloxane as the host material and by secondary foam molding. b. A total of 48 clinically diagnosed M4 patients and 52 patients with normal myelogram were included as the test and control groups, respectively. c. A method based on the microfluidic cell chip approach was established to detect CD14＋mono-cytes and to determine the positive rate and degree of MPO expression in the cells. d. The microfluidic cell chip technique was used to compare CD14＋monocyte MPO expression in M4 patients with that in the control. Results：a. The designed microfluidic single cell analysis chip allowed the entry of granulocytes into the corresponding microfluidic channels. Thus, blood cells were separated. Numer-ous ghost corpuscles surrounded the separated white blood cells （WBCs）. WBC morphology did not show obvious changes. b. The posi-tive rate of MPO expression and the activity of CD14＋monocytes in the bone marrow of M4 patients were significantly higher than those in the bone marrow of the control （P〈0.05）. Conclusion：A method based on microfluidic single cell technology was developed for the first time to analyze the MPO expression in CD14＋monocytes. CD14＋monocyte MPO activity in M4 patients was significantly higher than in the control. CD14＋monocyte MPO activity can be used as an auxiliary examination marker for clinical diagnosis.

关 键 词：单细胞分析 白血病 髓过氧化物酶 微流控芯片 

分 类 号：R733.7[医药卫生—肿瘤]